Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma

被引：2

作者：

Almokadem, Salah ^{[1
]}

机构：

[1] Penn State Hershey Med Ctr, Dept Med, Hershey, PA USA

来源：

CURRENT MOLECULAR PHARMACOLOGY | 2016年 / 9卷 / 03期

关键词：

Checkpoint inhibitors; cytokines; HNSCC; immune system; immunotherapy; PD-1; HUMAN-PAPILLOMAVIRUS; CANCER; RADIOTHERAPY; COMBINATION; SURVIVAL; PD-L1; TRIAL;

D O I：

10.2174/1874467208666150716120658

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Squamous cell carcinoma of the mucosal surfaces of the head and neck area exhibits a complex interaction with the host immune system that plays an important part in the evolution of the malignant process, in the resistance to different therapeutic modalities, and the ability of tumor cells to metastasize to distant organs. The recent advances in tumor immunology have transformed the field in onco-immunology from using non-specific immune-stimulant agents such as interferon and interleukins to the area of rationally targeted immunotherapy such as immune checkpoint inhibitors, which have shown promising results in early phase clinical trials.

引用

页码：226 / 230

页数：5

共 40 条

[1] Immunotherapy in head and neck cancer: current practice and future possibilities [J].

Agada, F. O. ;

Alhamarneh, O. ;

Stafford, N. D. ;

Greenman, J. .

JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2009, 123 (01) :19-28

[2] Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer [J].

Ang, K. Kian ;

Harris, Jonathan ;

Wheeler, Richard ;

Weber, Randal ;

Rosenthal, David I. ;

Nguyen-Tan, Phuc Felix ;

Westra, William H. ;

Chung, Christine H. ;

Jordan, Richard C. ;

Lu, Charles ;

Kim, Harold ;

Axelrod, Rita ;

Silverman, C. Craig ;

Redmond, Kevin P. ;

Gillison, Maura L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (01) :24-35

[3]

Bauman J. E., 2014, J CLIN ONCOL S, V5, P32

[4] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].

Bonner, James A. ;

Harari, Paul M. ;

Giralt, Jordi ;

Cohen, Roger B. ;

Jones, Christopher U. ;

Sur, Ranjan K. ;

Raben, David ;

Baselga, Jose ;

Spencer, Sharon A. ;

Zhu, Junming ;

Youssoufian, Hagop ;

Rowinsky, Eric K. ;

Ang, K. Kian .

LANCET ONCOLOGY, 2010, 11 (01) :21-28

[5] B7 family checkpoint regulators in immune regulation and disease [J].

Ceeraz, Sabrina ;

Nowak, Elizabeth C. ;

Noelle, Randolph J. .

TRENDS IN IMMUNOLOGY, 2013, 34 (11) :556-563

[6] Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma [J].

Cho, Young-Ah ;

Yoon, Hye-Jung ;

Lee, Jae-Il ;

Hong, Sam-Pyo ;

Hong, Seong-Doo .

ORAL ONCOLOGY, 2011, 47 (12) :1148-1153

[7] Phase 1b Trial of TLR8 Agonist VTX-2337 in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN) [J].

Chow, L. Q. M. ;

Eaton, K. D. ;

Baik, C. ;

Goulart, B. ;

Morishima, C. ;

Disis, M. L. ;

Manjarrez, K. ;

Dietsch, G. ;

Hershberg, R. ;

Martins, R. G. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02) :503-504

[8] Cancer-testis antigens in tumor biology and immunotherapy [J].

Clark, Carolyn E. ;

Vonderheide, Robert H. .

CANCER BIOLOGY & THERAPY, 2006, 5 (09) :1226-1227

[9] Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody [J].

Dewan, M. Zahidunnabi ;

Galloway, Ashley E. ;

Kawashima, Noriko ;

Dewyngaert, J. Keith ;

Babb, James S. ;

Formenti, Silvia C. ;

Demaria, Sandra .

CLINICAL CANCER RESEARCH, 2009, 15 (17) :5379-5388

[10] Cancer immunoediting: from immunosurveillance to tumor escape [J].

Dunn, GP ;

Bruce, AT ;

Ikeda, H ;

Old, LJ ;

Schreiber, RD .

NATURE IMMUNOLOGY, 2002, 3 (11) :991-998

← 1 2 3 4 →